Patent information
IP India · live recordAbstract
A pharmaceutical pack, comprising: i) a unit dose of vinorelbine or a pharmaceutically acceptable salt thereof; and ii) 50-300 mg of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide (“HKI-272”) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical pack further comprises instructions for dilution, mixing and/or administration, syringes, or needles.
Applicants
1Inventors
1Claims
14Specification
Show full textCollapse
BACKGROUND OF THE INVENTION 5 Breast cancer i s the most frequently diagnosed malignancy in women and one of the top two causm of cancer-related deaths in women worldwide. The incidence ofbreast cancer in the world rs maeasw and it is estimated that the disease will affect 5 mllion women in the next decade. Treatments permit control of symptoms, prolongation of survival, and maintenance of quality of life. However, m about 40% to 50% of all patients treated with curative intent, 10 incurable metastatic diseae WIU develop. Since there is no cure fox metastatic breast cancer, current therapeut~cg oals are palliative 111 several cancer types, deregulation of growth factor signaling is obaemed, associated ,math a hyperactivation of the ErbB receptors. The ErbB receptor family includes ErbB-1 (also known as HER-1, epidermal growth factor receptor (EGFR)), ErbB-2 (ak.a nvu or HER-2), 15 HER-3 (a k a ErbB-31, and HER-4 (ak a. ErbB-4). Overexpression of ErbB-1 is observed in non-small oell lung cancer (NSCLC) (40%-80%), breast cancer (14%-91%), and pancreatic cancer (30%-89%). In NSCLC, actmation by mutation of mpEcation of ErbB-1 also occurs in 10% to 30% of patients. Overexpression of ErbB-2, usually resultitkg from erbB-2 gene amplification, is observed 20 in tumor lissue in 25% to 30% of patrents of patients with metastatic breast cancer @BC) and is associated with malignant transfmation. ErbB-2 overexpression is! usually associated with a more aggressive tumor phenotype, worse overall prognosis, and faster relapse times at all stages of cancer development. In women with MBC, this overexpression confers a relative resistance to treatment with either anthracyclinelabkylator- or taxane-based chemotherapy. ErbB-2 25 overexpression in tumongenesis has been mainly studied in breast cancers but is also observed in other cancers. Among current therapeutics for cancers, specifically those characterized by overexpression of ErbB-2, are vinorelbine. trastummb and HKI-272. Vinorelbine, a semisynthetic vinca alkaloid having broad antitumor activity, acts throqgh microtubule 30 disruphon Vrnorelbine presents a lower neurotoxicity profile than vincristine or vinblastine. Vinorelbine has been shown to be less toxic to axonal microtubules than vincristine or vinblastme at therape- concentrations In studiea conducted on subjects with advanced breast cancer, treatment with vinorelbine as a single agent is at least as efficient as other chemotherap~ebs ut with a lower risk of toxicity. However, the risk of toxicity increases in parallel \nth the number of previous anticancer treatments. 5 Trasluzumab (HERCEPTIN@ dmg) 1s a humanized monoclonal antibody specific for the extracellular domam of ErbB-2. It presents s~gnificanct linical benefit and sigruficant antitumor activ~tyw hen used alone or m combination with taxanes in metastatic breast cancer in first-line treatment or in patlents whb have tumor progression after chemotherapy. Because of the improvement in survival, trastuzumab-based therapies have become standard of care for women 10 wth ErbB-2-positive RIBC. For women with advanced or metastatic disease, brwt canwr eventually recurs despite trastuzumab treatment. Trastuzumab-based therapy is also associated w~thpo tentla1 carbac toxicity. Certain breast cancer cells are resistant to trastunrmab due to the occurrence of secondaq~E rbB-2 mutations, such as trun~tionof extracellular domain ErbB-2 receptor Such mutations can resull in cancer cells which are not recognized by the antibody. 15 In recent studies, trastuzumab in combination with either vinorelbine or taxane (paclitaxel with or without carboplatin, or docetaxel) was utilized to treat subjects with ErbB-2-overexpressing MBC. As expected, the most frequent grade toxicity observed with the combination of trartuzumab and vinorelhie was neutropenia HKI-272 o a small molecule, irreversible pan-ErbB receptor inhibitor specific for 20 ep~dermagl rowth factor receptor WbB-1 or EGFR), ErbB-2 (HER-2), and ErbB-4 (HER-4). HRI-272 blocks W e activity of the receptor through bindii to the intracellular adenosine tiphosphate (ATP) blndmg site ofthe receptor. HKI-272 blocks ErbB receptor autophosphorylat~onin cells at doses consistent wthinhibition of cell proliferation. In v~tro, HW-272 alone mnh~b~ktsln ase activity of ErbB-1, ErbB-2, and HER-4, inhibits tumor cell growth 25 wth breast and lung bmor cell lines, and presents a potent growth inhibition of lung cancer cells resistant to gefitlnib or erlotinib. In vivo, HKI-272 blocks tumor growth in xmo@ animal models. Overall, HKI-272 is less potent against ErbB-1-dependeat !amom thanErbB-2-dependent tumors in vivo, even though it has equvalent activity against the 2 kinases in vrtro. There remans a need m the art for therapeutic methods, regimens, compositions, and kitr 30 whlch are useful m treating metastatic breast cancer and solid tumors. SUMMARY OF THE INVENTION This invention addresses the need in the art by providing regimens, compositions and methods using aHKI-272 compound and a vinoreIbine compound for the treatmat of cancers, such as solid tumors and metastatic breast cancer 5 In one aspectn regimens for treating a neoplasm in a subject are provided aad include admnustering a vinorelbine compound and administering a HKI-272 compound. Des~rablyt,h e vinorelbine compound 1s vinorelbine and the HKI-272 compound is HKI-272. In one embo&ment, the neoplasm is breast cancer. In another aspect, aregimen for treating a solid tumor associated with overexpression or 10 ampllficabon of HER-2 in a subject is provided, wherein one cycle of the regimen includes 21 days. The regimen includes orally W s t e r i n g at least one unit dose of HKI-272 starting on day 1 of the cycle and inlTavenousty administering at least one unit dose of vinorelbine on days 1 and 8 of the cycle m a further aspect, a regimen for treating a metastatic cancer associated with 15 overexpression or amplification of HER-2 m a subject is provided. One cycle of the regimen includes 21 days and the regimen includes orally administering at least one unit dose of HRI-272 starting on day 2 of the cycle and intravenously administering at least one unit dose of vinorelbine on days 1 and 8 of the cycle. In still another aspect, a product comprising avinorelbine compound andHKI-272 20 compound is provided as a combined preparation for simultaneous, separate or sequential use in lreating a neoplasm in a mammal In ! cr, a fuaher aspect, a pharmaceutical pack for treating a neoplasm in one individual mammal is provided and includes (a) at least one unit dose of vinorelbiie; and (b) at least one unit dose of HKI-272 25 In another aspect, a pharmaceutical composition is described and contains vinorelbine, HKI-272, and at least one pharmaceutically acceptable carrier. In sail another aspect, a method or treating aneoplasm assodated with overexpression or amplifi~cationo f HmR-2 in a mammal in need thereof is provided and includes administering a unit dose of a vinorelbine compound and administering aunit dose of aHKI-272 compound. 30 Other aspects and advantages of the invention will be readily apparent from the following detruled descripaon of the invention DESCRIPTION OF THE INVENTION This invent~onp rovides compositions, methods, and regimens using a combination of a HKI-272 compound and a vinorelbine compound for the treatment of cancers. This invention 5 provides m one embodiment composrtions comprising HKI-272 and vinorelbine for the treatment of neoplasms Also provided are products containing HKI-272 and vinorelbine formdated for simdtyeous, separate or sequential use in treating neoplasms in amamrnal. The invenfion is also usefui as an adjuvant andlor neoadjuvant therapy of earlier stages of breast cancer The inventLon provides, in another embodiment, methods for the combined use or 10 administration of a HKI-272 compound and vinorelbhie compound. The Therapeutic Regimen and Its Components Without wishing to be bound by theoiy, the inventors hypothesize that the combination of HKI-272 and vinorelbine for treating a neoplasm is desirable because HKI-272 targets the 15 intracellular ErbB-2 kinase rather than the extracellular domain Thus, this combination has d~fferenmt echanisms of sensitivtty and resistance and then presents an advantage over the therapeutic combination of trastmmab and vinorelbine. Further, the combination of HKI-272 and vinorelbine is anbc~patedto be more effective than combinations of vinorelbine with other pan-ErbB ihbltors due to the tyrosine b a s e inhibition activity ofHKI-272 through an 20 irreversible binding at a targeted cysteine residue hi the ATP bmding pocket of the receptor. Tbese methods, ccmbmahons and produets are useful in the treatment of a variety of neoplasms, partioularly those associated with overexpression or amplification of HER-2. In one embodiment, the neoplasm is a solid tumor or an advanced solid tumor. In a further embod~mentt,h e neoplasm is metastatic. In another embodiment, neoplasms that may be treated 25 as described herein include, e g , lung cancers (such as bronchioalveolar carcinoma and non small cell lung cancer), breast cancers (such as metastatic breast cancer andHER-2 -positive breast cancer), prostate cancers, myeloma, head and neck cancer, transitional cell carcinoma, small cell and large cell neuroendow~nec arcinoma of the uterine cervix In still another embohment, the neoplasm is resistant to trastuzumab. The regimens, methods, and compositions described herem include the concment, simultaneous, sequential or separate administration of the components, i.e., a m - 2 7 2 compound and a vinorelbme compound The term "composition" as used herein is mtended to cover both 4 pharmaceutical compositions in which 2 or more components are mixed, wmpositions of matter such as pharmaeeufical kits and packs in which the components are individually packaged for concurrent, simultaneous, sequentml, or separate administration. In one aspect of the invention, "acombination" includes simultaneous adminkation of theHKI-272 and vinorelbiie 5 compounds. In a further aspect ofthe mvention, "a combination" indudes sequential admnistration of the HKI-272 8nd vlnorelbine compounds. In one embodiment the HKI-272 is admuustered before the vinorelbine compound In another embodiment the vinorelbine compound is admimstered before them-272 wmpouud In another aspect, "a combination" includes separate administration of the HKI-272 and vinorelbine compounds in a particular 10 therapeutic regimen In which the two components of the combination are administered at specific bmea and amounts with respect to each other. In one embodiment, the combination of the HIU- 272 and vinorelbine compounds produces a more beneficial therapeutic effect tban that achievable by the administration of either aHKI-272 compound alone or a vinorelbiie compound alone. Where the admirustration of those agents is sequential or separate, the delay in 15 adnnnistering the second component should not be such as to lose the benefits provided the combination therapy. In one embodiment, the combination of the HKI-272 and vinorelbine compounds is particularly well suted for treatment of metastatic breast cancer. In another embodiment, the combination of the HKI-272 and vinorelbine compounds are well suited for treatment of breast, 20 kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, and lung), and polycystic kidney disease & wed herein a ~edxc ept wherenoted, the terms "individual", "subject" and "patient" are used interchangeably, and refer to any anitnal, including mammals, preferably doe, rats, other rodents, rabbits, dog, cats, swine, cattle, sheep, horses, non-human primates, and humans. 25 Desirably, the term "individual", "subject!' or "patient" refers to a human. In certain circumstances, these terms refer to experimental animals such as rabbits, rats, md mice, and other mmals In most embo&mants, the subjects or patients are in need of the therapeutic treatment. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to \vhlch the HKI-272 and vmorelbine compounds can be adminiswed. In one 30 embodiment, to ident~fys ubject patients for treatment according to the methods of the invention, accepted screening methods are employed to d e t m e risk factors associated with a targeted or suspected dlsease or conhtion or to determine the status of an existing disease or condition in a 5 subject These screening methods include, e.g., conventional work-ups to determine risk factors that are associated with the targeted or suspected disease or condition. These and other routine methods allow the clmcian to select patients in need of therapy using the methods and formulations of the present inventton. In one embodiment, the "individual", "subject" or "patient" 5 may have had no previously chemotherapeutic treatment. In another embodiment, the "individual", "subject" or "patient" may have previously undexgone chemotherapeutic treatment. In another embodiment, the "individual", "subject" or "patient" may have previously been administered an aniloquinwoline class inhibrtor In a further embodiment, the "individual", "subject" or "patient" may have previously been admitustered lapatinib orgeftinib as the 10 an~loqwnazolmec lass i&bitor Desirably, the blood count of the patient prior to treatment with the descnbed combmabons is stable enough to permit administration of the combinations descnbed herern In one embodiment, the neufrophil count of the patient prior to administratyon of the vlnorelbine and HKI-272 compounds is at least 1500. In another embodiment, the platelet count of the patient prior to administration of the vinorelbine and HgI-272 compounds is at least 15 100,000/1. As used herein, "am-272 compound'' refers, in one embodiment, to a compound having the following core structure' or a derivative or pharmaceutically acceptable salt thereof. Suitable derivatives may include, 20 e g., an ester, ether, or carbamate The core structure represented above is a particularly HKI- 272 compound, called HKI-272, whch has the chemical name (E)-N-{4-[3-~hloro4{2-pyridinylmethoxy) anilino] -3-cyano-7-ethoxydquinolirr,1}-4-(dime~lamino)-2-butenamide. In one embodtment, the HKI-272 compound useful in the compositions and methods described herein is HKI-272. 2.5 In another enlbod~menta, n HKI-272 compound has the structure; 6 wherein: R' is halogen; R2 is pyr~dlnyl,%uophenyl, pyrirmdmyl, thiazolyl, or phenyl, whereinI? is optionally 5 substituted with up to three subshtuents; R~ is 0 or S; R4 is CH3 or CHZCROCH~; R' is CH3 or CHaCH3, and nls 0011 The tm "halogen" as used herern refers to el, Br, I, and P. These HKI-272 compounds, of which HKI-272 is a species, are characterized by the ability Lo act as potent HER-2 mhibitors. &ee @.g.U, S Patent Nos. 6,288,082 and 6,297,258 and US Patent Application PublicztionNo. 2007/0104721, which are hereby incorporated by rehrence These compounds and their prepmation are described in detail in US Patent 15 Application Publication No 200510059678, which is hereby incorporated by reference. For convenience, "am-272 compound" is used throughout this specification However, any compound of the structure(s) provided above can be substituted for HKI-272 in the combinations described m detail below. HW-27% other HKI-272 compounds, and methods of making and farmdating same have 20 been described See, e g , US Patent Apphcation PublicationNo. 2005/0059678 and US Patent No 6,002,008, which are hereby incorporated by reference. The methods described in these documenb can also be used to prepare the substituted 3-quinoline compounds used herein and are hereby incorporated by reference. In add~tlonto the methods describedin these documents, International P&nt Publ~cationN os. W0-96/33978 and WO-96f33980, which are hereby 25 incorporated by reference, describe methods that are usell for tlle preparation of these HKI-272 compounds Although these methods descnbe the preparation of certainquinazolines, they are also applicable to the preparation of correspondingly substiluted 3-cyanoquindines and are hereby incorporated by reference. As used herem, the term"a vinorelbine compound" means vinwelbme or a 5 pharmaceubcally acceptable salt thereof, which has broad antitumor activity and that acts through szuc~tubuled isruption See, Widakowlch et al., Anticancer Agents Mad. Chem., 8(5) 488-406 (hule 20(18) and Wissner et al., Arch. Phm. (Weinhe*), (May 20,2008 epublicaaon) The term rncludes the neutral vrnorelbine compound, r.e., 4-(acetyloxy)-6,7- ~dehydro-l5-((2R,6~S)-4-ethyl-1,3,G~7,K,9-hexohydro-8-(~tho~carbonyl)-2,6-m&ano- 10 2H-aze~ino~4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-m&mye1t~h yl ester, (28,3j3,48,5a, 12R, 1%)-aspidosperrmdme-3-carboxplic acid (vinorelbine; tradename: Navelbine). V~norelhinea nd its pharmaceuticaIly acceptable salts are available from commercial vendors incluang AdvenhdSD Pharmaceuticals (SDP-O12@ drugdrug), Hana (ALOCREST@ drug), and Inex Pharmaceuticals Corp. (INX-0125TM drug), and other viaorelhine compounds, including 15 those discussed in US Patent No 7,235,564, which is hereby incorporated by reference. In one emhodtment, a vmorelbine compound includes a compound with a s t m c t d similarity to the tnorelbine compound structure below, e.g , compounds with a similar alkaloid structure that ha^ e been mohfied to enhance therapeutic benefit. The preparation of vinorelbine compounds are described by Langlois et al., in J. Am. Chem SOC 98,7017-7024 (1976); and by Mangeney et al.,in Tetrahedron, 35:2175-2179 (1979) The HKI-272 and ~lnorelbmnec ompounds and corresponding pharmaceutically acceptable salts or esters thereofinclude isomers either individually or as amixtme, such as enantiomers, diastereomers, and pcslQonal isomers. "Pharmaceutically acceptable salts and esters" refers to salts and esters that are 5 pharmaceutically acceptable and have the desued pharmacological properties. Such salts include, e.g., salts that can be formed where acikc protons present in the compounds are capable of reacting with inorganic or organic bases Suitable inorganic salts include, e.g., those formed with the alkali metals or alkaline earth metals, e.g. sodium and potasslum, magnesium, calcium, and a l m m Suttable organlc salts include, e g , those formed with organic bas= such as the 10 amine bases, e.g ethanolamine, dlethanolamine, triethanolamine, trom&bdne, Nmeihylglucmncne, and the like. Pharmaceutically acceptable salts can also include acid addition saIts formed from the reachon of basic moieties, such as amines, in the parent compound with morgaulc aids (e g. hydrochloric and hydrabromic acids) and organic acids (e.g. acetic acid, citnc acid* maieic acid, md the alkane-and arene-sulfonic acids such as methanesulfb~ca cid 15 and benzrnesulfonic aad) Pharmaceutically acceptable esters include esters formed from carboxy, sulfonyloxy, and phosphonoxy groups present in the compounds of the invention, e.g., C1.6akyl esters. When there are two acidic groups present, apharmaceutically acceptable salt or ester can be amonoacid-mono-salt or ester or a di-salt or ester; and similarly where there are more than two aeidii 20 groups present, some or all of such groups can be salified or esterified. Compolmds d i d herem may be present in unsaltfied or unesterified form, or in salified andlor esterified form, and the naming of such compounds is intended to include both the original (unsalified and uoester~fied)c ompound and its pharmaceutically acceptable salts and esters. Also, one w more compounds utllized herein may be present in more than one stereoisomeric form, and the naming 25 of such compounds is intended to include dl single stereoisomers and all mixtures (whether racemic or otherw~se)o f such stereolsomers. Pharmaceutically acceptable salts of the HKI-272 and vmorelbie compounds with an acidic mo~etym ay be formed from organic and inorganic bases mcluding e.g., salts with alkali metals or allraline earth metals such as sodium, potassium, litbium, calcium, or magnesium or 30 organic bases and N- tetraalloilammonium salts such as N-tetrabutylemmoniumabuoum salts. Similarly, when one or more compound utilized herein contains a basic moiety, salts mrry be formed from organic and inorganic acids. For example, salts may be formed from acids such 9 as acetic, propionic, lacuc, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, aalic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this lnvenhon contains a basic functional group. Other 5 slutable exalyles olpharmaceu~callya cceptable salts mclude, but are not limited, to sulfate; atrate, acetate, oxdate; chloride; bromide; iodide; nitrate; bisulfate; phosphate; acid phosphate; isonicotinate; lactate; salicylate; acid citrate; tartrate; oleate; tamate; pantothenate; bitartrate; ascorbate, sucanate; malea*; gentsinate; fumarate; gluconata; gluoaronatq saccharate; formate; benzoate; glutamate; methanesulfonate; ethanesulfonate; betlzenesulfonate; p-toluenesulfanate; l o pamoate (1.e , 1,1'-m&ylene-bis-(2-hydro~3-naphthoa~; and salts of fatty acids such as caproate, laurate. wristate, palmitate, stearate, oleate, linoleate, and linolenate salts. In one embodiment, the vinorelbiie compound is vinorelbime tarttate. The compounds can dso be used in the form of esters, carbarnates and other conventional ester forms, also referred to herein as prodrug forms, which when administered in suchfwm, 15 convert to the active moiety I??-wwE. xemplary ester forms of the compounds of this invention mclude, but are not limited to, straight chain alkyl esten having from 1 to 6 carbon atoms or branched cham alkyl gmups containing 1 to 6 carbon atoms, including methyl, ethyl, propyl, butyl, 2-methylpropyl and 1,l-dimethylethyl esters, cycloalkyl esters, akylaryl esters, benzyl esters, and the like. Accordmgly, a pharmaceutical composition is provided and contains effective amounts of the HKI-272 and vinorelbine compounds in combination or association with one or more phamawu~callyac ceptable carrier. Suitable examples of pharmaceutical carriers used herein include, but are not limited to, excipients, dituents, fillers, disintegrants, lubricants and other agents that can function as a carrier. The term "pharmawutically acceptable excipient" me~ns8 n 25 excipient that is useful in preparing a pharmaceutical composition that is generally safe, nontoxic, and desirable, and mcludes excipients that aze acceptable for veterinary use as well as for human pharmaceutical use. Such excipients can be solid, liquid, semisolid, or, in the case of an aerosol composlhon, gaseous. Pharmaceutical compositions are prepared In accordance with acceptable pharmaceutical procedures, such as described in Remingtons Phamaceutical 30 Scienm, 17th edition, ed. Alfonoso R Gennaro, Mack Publishing Company, Easton, Pa (1985). Pharmace&cally acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable. Suitable pharmaceutically-acceptable excipients or 10 carriers for a tablet or caplet formulalxon include, e g., inert excipienls such as lactose, sodium carbonate, calcium phosphate or calctum carbonate, granulating and disintegrating agents such as com starch or a l g t ~acc ~db; mding agents such as gelatin or starch; lubricatmg agents such as magnesium slearate, stearic acid or talc; preservative agents such as ethyl or propyl4- 5 liy drox) benzoate, and anti-oxidants, such as ascorbtc acld. Tablet or caplet formulations may be uncoated or coaled either to mod@ their msintegration and the subsequent absorption of the actme ingredient wittun the gastrointestinal tract, or to improve their stability and/or appearance uslng con~fent~oncaola ting agents and procedures well known in the art. In one embodiment, the we~ghot f the tablet 1s at least about 20,30,40,50, 60, or 70 mg. 10 Optional Components of the Regimens The regimens described herein may also include the administration of other agents. In one embodiment, the regmen further includes administration of a tawane, e.g., docetaxel and paclitaxel [a g , a suspension of paclitaxel bound to albumen nanoparticles, which is available as 15 the ABRAXANEBfi reagent]. Paditaxel may also be administered on a weekly schedule at doses 60-1 00 mg/mz administered over 1 hour, weekly, or 2-3 weekly doses followed by a one week rest In one embodiment, paclitaxel is administered intravenously over 3 hours at a dose of 175 mg/m2, optionally followed by cisplatin at a dose of 75 mg/mZ; or paclitaxel administered ~ntravenouslyo ver 24 hours at a dose of 135 mg/m2, optionally followed by cisplatin at a dose of 20 75 mglm2. In patlents previously treated with therapy for carcinom paclitaxel can be injected at several doses and schedules. However, the optimal regimen is not yet clear. The recommended reglmen 1s pahtaxel 135 mdm2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks These doses may be altered as needed or desired. In another embodiment, other active agents may be included in a combination with an 25 HKI-272 oompound and vinorelbine compound and include, e.g., chemotherapeutic agents, such as allcylating agents or mTOR irhbitors (rapamycin and derivatives thereof); hormonal agents (LC., estramustine, tamoxifen, toremifene, anastrozole, or letrozole); antibiotics (i.e., plicamycin, bleomyctn, rmlowantrone, idarubicin, dactinomycin, mitomycin, or daunorubicin); other antimitotic agents ( I e , vinblastine, vincristine, teniposide); topoisomerase inhibitors (i.e.. 30 topotecan, irinotecan, etoposide, or doxorubicin, e.g., CAELYX" or DOXILIB reagents, pegylated I~posomaId oxombicm hydrochloride); and other agents (i.e., hydroxyurea, aleetmne, ntuxlmab, paclitaxel, doeetaxel, L-aspmginase, or gemtuzumab ozogamicin); 11 b~ochermcaml odulatmg agents, unatib, EGFR inhib~torsu ch as EKB-569o r other multi-base inhibitors e g , those that targets serine/threonine and receptor tyrosine kinases in both the tumor cell and tumor vasculature, or immunomodulatom (i.e., mterferons, IL-2, or BCG). Examples of sultable interferons include interferon a, interferon P, interon y, and mixtures thereof. 5 Desuably, the combination of the HKI-272 compound and vinorelbine compound may be further combined wth antineoplastic alkylating agents, e.g., those described in US Patent Application PublicationNo. 2002-0198137, which is hereby incorporated by reference. Antlneoplastic alkylating agents are roughly classified, accordmg to thdr structure or reactive molety, into several categories which includemtrogen mustards, such as MUSTARGEN@ drug 10 (meclorethmne), cyclophosphamide, ifosfamide, melphalan, and chlorambucil; azidines and epoxldes, such as thiotepa, mttomycin C, dianhydrogalactitol, and dibromodulcitol; alkyl sulfmates, such as busulfaqnitrosoureas, such as bischloroe~lnitrosourea(B CNU), cyclohexyl-chloroethyInitrosourea (CCNU), and methylcyclohexyl~oroethy~nitrosourea (MeCCNUJ, hydrazine and triazine derivatives, such as procarbazine, dawbazine, and 15 temozolomide; streptazom, melphalan, chlorambucil, camwheq methclorethamine, 1omushne)and platmum compounds. Platinum compomds are platinum containing agents that react preferentially at theN7 yosiaon of guanine and adenine residues to form a variety of monofunctional and biictional adduets, [Johnson S W, Stevenson J P, O'Dwyer P J. Cisplatin and Ifs Analogues. In Cancer Princ~ples& Practice of Oncology 6'~dition. ed. DeVitaV T, 20 Hellman S, Rosenberg S A. Lippincolt Williams & Wilkins. Ph~ladelphia2 001. p. 378.) These compounds include c~splahnc, arboplatin, platinum IV compounds, and multinuclear platinum complexes Representative examples of alkylatmg agents including meclorethamine (injectable; MUSTARGENB drug), cyclophosphamide (injectable; cyclophosphamide, lyophilized CYTOXANCC drug, or NEOSAR5 drug; oral tablets cyclophosphamide or CYTOXAN@ drug), 25 ifosfamide (injectable; JFEX), melphalan (injectable, ALKERANB drug and oral tablets, ALKERAN@ drug), chlorambucil (oral tablets, LEUKERAN@ drug), thiotepa (injectable, thiotepa or THIOPLEXQ drug), mitomycin (injectable, mitomycin or MUTAMYCIN@ drug), bmulfan (injectable, BUSULFEX@ drug; oral tablets, MYLERANB drug), lomustine (oral capsules, CEENU), carmusbne (mtracranial implant, GLIADEL), injectable (BICNU), 30 procarbazine (oral capsules, MATULANEm w)te,m ozolomide (oral capsules, TEMODm@ drug), cisplatin (injectable, usplalln, PLATINOLB drug, or PLATINOLaAQ)., carboplatin (injectable, PARAPLATIN@ drug)? and oxaliplatin (ELOXATIN@ drug). 12 In another embodiment, a combination described herein may further include an antmeoplaac antimetabohte, as descnbed in US Patent Application PublicationNos. 200510187184 or 200210183239, which are hereby incorporated by reference. As used herein accordance, the tern "mtimetabolite" means a substance which is lit~ct~ralsliym ilar to a critical 5 natural interndate (metabolite) m a biochemical pathway leading to DNA or RNA synthesis which is used by the host in that pathway, but acts to inhibit the completion ofthat pathway (i.e., synthesis of DNA or RNA). More specifically, antimetabolites typically function by (1) camp+ with metabolites for the catalytic or regulatory site of a key enzyme in DNA or RNA synthesis, or (2) substitute for ametabolite that is normally incorporated into DNA or RNA, and 10 thereby producmg aDNA or RNA that cannot support replication. Major categories of antimetabolites include (1) folic acid analogs, which are inhibitors of dihydrofolate reductase (DHFR); (2) purine d o g s , which rmrmc the natural purines (adenine or guanine) but are structudly different so they competitiveIy or irreversibly inhibit nuclear proces~ingo f DNA or FWA; and (3) pynmidiie analogs, which mimic the natural pyrimidines (cytosine, thymidine, 15 and uracil), but are structurally different so thy competitively or irreversibly inhibit nuclear processing of DNA or RNA Representative examples of antimetabolites include, without limtallon, 5-Fluorouracil(5-FU; 5-fluoro-2,4(1H,3H)-pyrimidinedione; topical cfeam, FLUOROPLEXB or EFUDEXm drugs; topical solution, PLUOROPLEX@ or EFUDEX@ drugs; injectable, ADRUCILm drug orflurou~acil))fl,o xwadine (2'-deoxy-5-fluorouridine; 20 bjectable, FUDR or floxuradine), thiogwnme (2-armno-1,7-d1hydro-6-H-punne-6-thi(moera l tablets, thiogpmne), cytarabine (4-amino-l-(~)-D-arabinofuranosyl-2(1H)-~timidinone; liposomal injectable, DEPOCYT@ reagent, liquid injectable, cytarabine or CYTOSAR-U@ drug), fludarabme (9-H-Purin-6-amine~-fluoro-9-(5-O-phosphono-@~D-a-rabino~msyI; liqwd injectable, FLUDARA), 6-Mercaptopdne (1,7-dihydro-6H-purin66-thime; oral tabIets, 25 PURINETHOL)., methotrexate (MTX, N-14-[[[2,4-diamino-6-pterid~nyl)methyl]methylarmno]benzoyl]-lc acid; liquid injectable, methotrexate sod~umor FOLEX; oral tablets, methutrexrrte sodium), gemcitabiie (2'-deoxy-2',2'-d~fluorocyhdmem onohydrochlonde ((j3)-isomer); liquid injectable, GEMZAR), capedtabine (5'-deoxy-5-fluoro-N-[(pentyloxy)mbonyl]-cytidineo ral tablet, XELODA), pentostatin ((R)-3-(2- 30 deoxy-(beta)-D-erythro-pentofuranosyl)-3,6,7,8-t&~dro~~o[4,5-d][l,3]&~~-8-01; hqu~dul j ectable, NIPENT). eetrexate (Z4-diamino-5-methy1-6-[(3,4,5- Inmethoxymlino)methyl]qu~nazoline mono-D-glucuronate; liqurd injectable, NEUTREXIN), cladribine (2-chlo~o-6-amino-9-(Z-deoxy-(~)-D-e~openko-furanopsuyri1n)e ; liquid injectable, LEUSTATIN) The term "biochemcal lnodulahng agent" is well known and understood to those skilled 5 m the art as an agent given as an adjunct to anti-cancer therapy, which serves to potentate its antineoplastic activity, as well as cotmteract the side effects of the active agent, e.g., an antrmetabolite. Leucovonn and levofol~natea re typically used as biochemical modulating agents for methotrexate and 5-FU therapy. Leucovorin (5-fonnyl-5,6,7,8-tetrahydrofolic &ld) is commetc~allya vailable as an injectable liquid (leucovorin calcium or WELLGOVORIN) and as 10 oral tablets Oeucnvorin caIcium). I.evofolinate (pharmacologically acme isomer of 5-formyltetrahydroLolic acid) is commercially available as an injectable containing (ISOVORCN) 01 as oral tablets (ISOVORIN) In stdl another embodiment, the combination further includes a kinase inhibitor. Partml arly desirable h a s e Inhibitors include multi-kinase inhibitors target serinelthreonine and 15 receptor tyrosint; kinases in both the tumor cell and tumor vasculature. Examples of suitable kinase inhibitors include, without limitation, sorafenib (BAY 43-9006, commercially available as NEXAVAR), whch has been granted Fast Track status by the FDA for metastatic renal cell cancer, zamestra (R115777, tipifornib), suntinib (SUTENT), and other campounds that farget Ras/Raf/MEK and/or MAP lanases mcludtng, e.g., avastin, ISIS 5132, and MEK inhibitors such 20 as CI-1040 or PD 0325901 Alternabvely, the kinase inhibitor may be administered to the pabent pnor lo or subsequent to treatment \nth the vinorelbine compound and/or HKI-272 compound In stdl filrther embodiment, the combination may include an anti diarrheal. One of skill in the art would readiiy be able to select a suitable antidimheal for use herein including, mthout 25 limitation, loperamide or diphenoxylate hydrochloride and atropine sulfate. Alternatively, the anti-diarrheal may be admmistered to the patient prior to or subsequent to treatment with the vinorelblne compound and/or HKI-272 compound. In a f d w embodiment, the combination further contains an antiemetic agent. Examples of antiemetic agents mclude, w~thoulti mitation, metoclopramide, Dolasetron, Granisetron, 30 Ondansel~onT, ropisekon, and Palonosetron, among oIhers. Alternatively, the antiemetic may be adrmntstered to the paSlent prior to or subsequent to treatment with the vinorelbine compound and/or HKT-272 compound. In ye1 a further embod~mentt,h e combiition also contains an antihistamine. Examples oC antihistamu~esm clude, *out limitation, Cyclizine, Diphenhydramine, Dimenhydrinate 5 (Gravel), Mechzme, Promethaztne pentazine, Phenergan, Promacot), or Hydroxyzine, among others. Alternatively, the ant~h~staminmea y be administered to the patient prior to or subsequent to treatment with the vinoreibme compound andfor HKI-272 wmpovnd In yet another embodiment, the wmbinatio~ml ay include a growth factor to prevent and/or treat neutropenia Such growth factors may readily be selec5ed by those skill in the art 10 according to practice guidelines from the American Society of Cluiical Oncology (ASCO, 2006). Alternatively, the growth factor may be administered to the patient prior to or subsequent to treatment with the vinorelbine compound andlor HKI-272 compound. Administration of the CompositionslCombinations 15 As used herein, the term "effective amount" or "pharmaceutically effective amount" refers to the amounl of achve compound or phamaceical agent that elicits the biological or medicinal response in a tissue, system, animal, individd or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following (1) preventing the disease; e.g., preventing a disease, condition or disorder in an 20 inlvrdual that may be predisposed to the disease, condition or disorder but doe$ not yet expmence or d~splayth e pathology or syrnplomatology of the disease; (2) &biting the disease; e g , inhibitmg a dlsease, wnd~t~orn d isorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder Q.e., arresting or slowing further development of the pathology andlor symptomatology); and (3) ameliorating the disease; 25 e.g., ameliorating a disease, condition or disorder in au individd that is experiencing or displaying the patholow or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or syrnptomatology). For example, an effective amount," when administered to a subect to treat cancer, is sufficient to Inhibit slow, reduce, or eliminate tumor growth in a subject havlng cancer 30 Use of a combinahon dthe HKI-272 compound and vinorelbine compound also provides for the use of combmations of each of the agents in which one or both agent is used at subtherapeutically effectrve dosages. Subtherapeutically effective dosages may be readily 15 determined by one of skill in the art, in vlew of the teachings herein. In one embodiment, the subtherapeutically effective dosage is a dosage which is effective at a lower dosage when used in the combinattan regimen described herein, as compared to the dosage that is effective when used alone Also provided are one or more of the active agents in the combinations herein to he used 5 in a supratherapeuhc amount, c.e., at a higher dosage in the combination than when used alone. In this embodiment, the other active agent(s) may be used in atherapeutic or subtherapeutic amount. The term "treating" or "treatment" refers to any indicia of success in amelioration of an mjury, pathology, or condition, including any objective or subjective parameter such as 10 abatement; remission, drmimshmg of symptoms or making @e injury, pathology, or condition more tolerable to the patient, slowng the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving asubjeot's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical exarmnation, neurological examination, andlor psychiatric 15 evaluation. Accordingly, the term "treating" mcludes the administration of the HKI-272 and vinorelbine compounds to a subject to prevent or delay, to alleviate, or to anesf or inhibit development of the symptoms or con&tions associated with cancers, mcludmg tumor growfh assoc~atedw ith cancer A skllled rnedmal pramhoner will know how to use standard methods to d e t e m ew hether apai~enits suffering from a disease sssociated with cancer by examining the 20 patlent and detennuung whether the patient is suffering from cancer. As used herein, the term "providing with respect to prowding a HKI-272 compound and a vinorelbine compound, means either directly administering the HKI-272 compound and vinorelbine compound, or administering aprodrug, derivative, or analog which will form an effective amount ofthe HEU-272 compound andor Yinorelbme compound within the body. 25 The invention therefore includes administering an HKI-272 compound and vinorelbine compound to a patient for the treatment of aneoplasmin apatient. In one embodiment, the HW- 272 compound is adm~msteredse parately fromthe vinorelbine compound In a further embodinienl, the HKI-272 compound is administered prior to the vinorelbine compound. In another embodiment, the HKI-272 compound is administered subsequent to the vinorelbine 30 compound, In still another embodimentt the HKI-272 compound and the vinorelbine compound are admltustered simultaneously, but separately. In one embodiment, the HKI-272 compound and the vinorelblne compound are administered together as a combinedpreparation 16 In one embodiment, a product contam an HKI-272 compound and vinorelbine compound as a comblned preparation for simultaneous, separate or sequential use in treating a neoplasm in a mammal in need thereof. In one embodiment, the EW-272 compound is separately formulated from the vlnorelblne compound. In another embodunenf a product 5 contains the HKI-272 compund and the vlnorelbine compound as acombined preparation for sim~taneouss, eparate or sequential use in a neoplasm in a mammal in need thereof. In one embodiment, a pharmaceutical pack contains a course of treatment of aneoplasm for one individual mammal, where~nth e pack contains units of an W-272 compound in unit dosage form and units of a vinorelbine compound in unit dosage farm. In another embodiment, a 10 pharmaceutical pack contains a course of treatment of a neoplasm for one individual mammal, whernn the pack contains unlts of an HKI-272 compound in unit dosage form and units of a vlnorelblne compound in untt dosage form. In yet another embodiment, a pharmaceutical pack as described herein contains a come of treatment of metastatic breast cancer for one individual m d . Adm~nistrationo f the individual components or a composition containing two or more of the indiv~dualc omponents may employ any suitable mute. Such routes may be selected fiom, e.g., oral, mnixamnous (i.v.), respiratory (e g , nasal or intrabronchial), infusion, parentera1 (aside from1 v ,s uch ns intral~ional~, ntraperitoneaal nd subcutaneous injections), intraperitoneal, transdermal (including all administration across the surface of the body and the inner linings of 20 bodily passages includmg epithelial and mucosal tissues), and vaginal (including intrauterine administration) Other routes of administration are also feasible and include, without limitation, I~posome-mediatedd ellvety, topical, nasal, sublingual, metheral, intrathecal, ocular or otic delivery, implant, rectal, or mntranasal. W l e the components may be dehered viathe same route, a ptoduct or pack described 25 herem may co~ltiuna vmorelb~nec ompound for deliveg by a diierent route than that of an HKI- 272 compound, e.g., one or more of the components may be delivered orallyYw hile one or more of the others are administered intravenously. In one embodiment, the HKI-272 compound is prepared for oral delivery and the vinorelbine compound is prepared for intravenous delivery. In another embedment, both the HKI-272 and vinorelbine compounds are prepared for intravenous 30 delivery. In still another embodiment, both the HKI-272 and vinorelbine compounds are prepared for oral deliven. Optionally, other active components may be delivered by'the same or different routes as the HKI-272 andlor vinorelbine compounds. Ofher variations would be apparent to one sktlled in the art 111 s~il la nother embodiment, the compounds or components of the therapeutic regimen are adrmlvstered once aweek In certain situahons, dosing with the HRI-272 compound may be 5 delayed or disconhnued for a brief period [e.g., 1,2 or three weeks) during the come of treatment Such a delay or discontinuation may occur once, or more, during the course of treatmant. The effective amount is known to one of skill in the art; it will also be dependent upon the form ofthe HKI-272 compound. One of skill in the art could routinely perform empirical ackvity tests Lo determine the bioacti~ityo f them-272 compound in bioassays and 10 thus determine a suitable dosage to administer. The HKI-272 and vlnorelblne compounds or other optional compounds used in the combm&on and produots described hereinmay be formulated in any suitablemanner. However, the amounts of each compound in theunit dose can vary widely depending on thetype of wmposikon, regimen, size of a unit dosage, kind of excipients, and other factors well known 15 to those of ordinq skill in the art In one embodiment, the unit dose can contain, e.g., 0.000001 percent by weight (% w) to 10% w of either compound In another embodiment the unit dose can contain about 0 00001 Oia w to 1% w, with the remainder being the exeipient or excipients. The compositions described herein may be in a form suitable for oral adrmnistrafion, e.g., tablet, caplet, capsllle. buccal forms, troches, lozenges and oral liquids, suspensions or solutions: 20 pasenteral injecoon (ineludmg intravenous, subcutaneous, intramuscular, intravascular or snfus~on)e, .g., as a sterile solution, suspension or emulsion; topical administration, e.g, an omtment or cream; rectal admimstration, e g., a suppository, or the route of m a t i o n may be by direct Injection into the twnor or by regional delivery or by local delivay. In other embodiments, one or both components of the combination treatment may be delivered 25 endoscopicall~. ~ntratrachedlyi,n tralesimally, percutmeously, intravenously, subcutaneously, lntrapentoneally or intratumorally. In general the compositions described herein may be prepared m a conventlona1 man& usmg conventional excipients or carriers that are well knownin the att. Pharmaceutid compositions for oral use may also be in the form of hard gelatin capsules in whrch the active ingredient is mured with an inert solid excipient, e.g,, calcium carbonate, 30 calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil, such as peanut oil, liquid paraffin or olive oil. In one embodiment, one or bolh of said vlnorelbine compound and saidHKI-272 compound are delivered orally to said subject Capsules may contain mtures of the active compound(s) with inert fillers andlor diluents such a the phar~naceuticallyac ceptable starches (e.g, corn, potato or tapioca starch), 5 sugars, arhficlal sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelabns, gums, etc. Useful tablet ot caplet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disinteptants, surface modifyig agents (including surfactants), suspending or 10 stab~l~zinagge nts, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lawyl sulfate, microcrystalline cellulose, carboxymethylceUdose calcium, polyvinylpyrrolidone, gelatin, algihic acid, acaciagum, xanthan gm~s,o dium citrate, complex calcium carbonate, giycme, dex(ri11. sucrose, sorbltol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Preferred surface 15 mowing agents include nonionic and anionic surface mowing agents. Representative examples of surface modiiying agents mclude, but arenot limited to, poloxamer 188, benvllkonium chlonde, calcium stearate, cetosteasyl alcohol, cetomacrogol emulsi&ing WFS, sorbitan esters, colloidal s i l i c ~d~ oxldep, hosphates, sodium dodecylsulfate, magnesium alunitnum silicate, and tnethanolamine. 20 Oral SormulaUons herem. e g , tablets, caplets, or capsules described above, may utillze standard delay or time release formulabons to alter the absorption ofthe active compound(s). The oral formulabon may also consist of admimstenng the acbve ingredient in water or a fruit jmce, contaming appropriate solubilizers or emulsifiers as needed In some cases it may be desirable to administer the compolmds directly to the airways in 25 the form of an aerosol. The pharmaceutical forms slutable for injectable use include stenle aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterileinjectable solutions or dispers~ons In all cases, the form mwt be sterile and must be fluid to the extent that easy syringab~l~etxyr sts It must be stable under the cmditions of manufacture and storage and must 30 be preserved agmnst the contaminating acbon of microorganisms such as bacteria and fungi. The curler can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and 19 vegetable oils. Prefered mjectable fomulations containing vinorelbine are described in the art. In one embodiment, the compounds may be administered parenterally or in!zaperitonedly. Solutions or suspensions of these active compounds as aftee base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy- 5 propylcellulose. Dispersions can also be prepared in glycerol, liqlud polyethylene glycols and mixtures thereof in oils Under ordinary conditions of storage and use, these preparations may contam a preenatwe to prevent the growth of mcroorganisms. In one embodiment, one or both of the vinorelblne and HKI-272 compounds ate delivered intravenously. For use herem, transdermal administrations include all administrations across the surface 10 of the body and the inner linings of bodily passages including ep~theliaal nd mucosal tissues. Such administrations may be performed using the present compoundsdso r pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and supposltones (rectal and vaginal) Transdermal administration may be accomplished through the use of a transdermal patch containing the active compound and a carrier that is inert to the active 15 compound, is nontoxic to the skin, and allows dehvery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of fotms such as creams and ointments, pastes, gels, and occlusive devices. The creams and otnttnents may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active 20 ingredient my also be suitable. A variety of occlusive devices may be used to releae the active lngredtent into the blood stream such as asemi-permeable membrane covering a reservoir contammg the active lugreclient with or without a carrier, or amatrix containing the active ingredient Other occlus~ved evices are known in the literature, Suppository formulations may be made from traditional materials, including cocoa butter, 25 with or w~thoutth e addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such m polyethylene glycols of various molecular weights, may also be used. In another embodiment, one or both of the HKI-272 and vinorelbine wmpounds can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, 30 re , by employing ligands attached to the liposome, or attached directly to the oligonucleotide, thzt bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface cames ligands specific for target cellss,o r are 20 otherwise prererenhally dmcted to a specific organ, one can focus the delivery of one or more compound Into the target cells in vim. (See, e.g., Al-Muhammod, J. Micmencapsul. 13:293-306, 1996; Chonn, Curr Op~n Blotechnol. 6 698-708,1995; Ostro, Am J. Hosp. P h m 46:1576- 1587, 1989). Zn other cases, the preferred preparation of one or more of the components can be a 5 lyoph~lizedp owder. Encapsulating materials can also be employed with one or more of the compounds and the ten11 "composition" can include the active ingredient in combination with an encapsulating material as a formulation, with or without other carriers. For example, the compounds crm also be delivered as microspheres for slow release in the body. In one embodiment, microspheres can 10 be administered via intradermal injection of drbg-contaitiing microspheres, which slowly release subcutaneously (see Rao, J. Biomater SCIP. olym Ed. 7.623-645,1995; as biodegradable and mjectable gel formulations (see, e.g . Gao, Pharm Res. 12:857-863,1995); or, as microspheres for oral adrmtllstrakon (see, e.g., Eyles, J. Pharm. Phannacol. 49.669-674,1997). Both transdermal and mntradermal routes afford constant delivery for weeks or months. Cachets can 15 also be used in the delivery of the compounds of the present invention, e.g., anti-atherosclerotic med~caments. Dosages of the HM-272 Compound and Vinorelbme Compound 20 As is typical with oncology treatments, dosage regimens are closely monitored by the treating physician, based on numerous factors including the severity of the disease, response to the disease, any treatment related toxicities, age, and health of the patient. Dosage regimens are expected to vary according to the route of adminimation. The dosages and schedules described herelubefore may be varied according to the 25 particular disease state and the overall condition of the paent. For example, it may be necessary or des~rableto reduce the above-mentioned dosa of the components of the combination treatment in ordel to reduce toxlcrty Dosages and ~cbedulesm ay also vary 5 in addition to a combination of an HKI-272 compound and avinorelbine, one or more additional chemotherapeutic agents are used. Scheduling can be determined by the practitioner who is 30 treating any particular patient using his professional skill and knowledge. For the HKI-272 compound andlor vinorelbine compound, it is desired each compound of the combina&on of compounds is in the form of a unit dose. The term "unit dose" or "unit dose 21 form" as used herem describes a single dose form including, without limitation, tablets, caplets, capsules, powders in sachets or vials, saliae infusion bags, as described above. Un~dt ose forms contan &om about 0.1 to about 300 mg of a m - 2 7 2c ompound. In another embodimenf the unit dose form contains about5 to about 300 mg of the HKI-272 5 compound. In another embodiment, the m t dose form contains about 50 to about 300 mg of the HK1-272 compound. In a further embodiment, the unit dose form contains about 75 to about 300 mg of the be-272 compound In still a fmther embodiment, the unit dose form contains about 100 lo about 300 mg of the HKI-272 compound In yet another embodiment, the unit dose form contains about 120 to about 300 mg of the HKI-272 compound. In yet a further embodiment, the 10 unlt dose form contains about 160 to about 300 mg of the HKI-272 compound In another embomment. the unit dose form contains about 200 to about 300 mg of the HKI-272 compound. In yet another embodiment, the unit dose form contains about 240 to abovt 300 mg of the HKI- 272 compound. In a further embodiment, the unit dose form contains about at least about 120 mg. In still a father ehbodiment, the wit dose f m contains at least about 160 mg. In another 15 embodiment, the unit dose form contans at least about 240 mg. The HIU-272 compound can be administered, e.g., orally, at a dose range of about 0.01 to 100 &g. In one embedment, the HKI-272 compound is administered at a dose range of about 0 I lo about 90 mglkg. In another embodiment, the HKI-272 compound is administered at a dose range of about 1 to about 80 mglkg. In afurther embodiment, the HKI-272 compound is 20 adrmnistered at a dose range of about 10 to about 70 mgkg. In yet another embodiment, &e HKI- 272 compound is adnvnistered at a dose range of about 15 to about 60 mgbg. In still afurthm embobment, the be-272 compound is adrmnisteted at a dose range of about 20 to about 50 mg/kg. In another embodiment, the HKI-272 compound is administered at a dose range of about 30 to about SO mgikg. One of skill in the art could routinely perform empirical activity tests to 25 determine the bioactivity of the compound in bioassays and thus determine what dosage to administer. In one embodiment, the oral dosage of the HKI-272 compomdis at least about 700 =/week. In another embodiment, the oral dosage of the HKI-272 compound is about 800 mglweek to at Least to about 1700 mg/week In another embodiment, the oral dosage of the HKI- 30 272 compound is about 840 mg/week to about 1680 &week In another embodiment, the oral dosage of the HKI-272 compound is about 900 mg/week to about 1600 mgheek. In a further embodiment, the oral dosage of the HKI-272 compound is about 1000 mg/week to about 1500 22 mglweek In yet another embodmmt, the oral dosage of the HKI-272 compound is about 1100 mg/week to about 1400 mg/week In In a arther embodiment, the oral dosage of the HKI-272 compound is about 1200 mglweek to about 1300 mg/week Precise dosages are determined by the administering physician based on experience with the individual subject to be treated. Other 5 dosage regimens and variazlons are foreseeable, and are determined through physician guidance. Desirably, the patient is administered about 0.1 to about 50 mgkg of the vinorelbine compound In one embodiment, the patient is administered about 1 to about 30 mgikg of the vinmelbine compound. In another embodiment, the patient is administered about 5 to about 25 mgkg of the vinorelbine compound. In a further embodiment, the patient is admmistered about ' 10 10 to about 20 mgkg of the vinorelbine compound. In still a further embodiment, the patient is admnrstered about 20 mglkg of the vinorelbiie compound. Unit dose fonns contam about 0.1 to about 100 mg of a vinorelbine compound. In another embod~mentt,h e unit dose fom~co ntains about 1 to about 70 mg of the vinorelbiie compound. In another embohment, the unit dose form contains about 5 to about 500 mg of the vinorelbine 15 compound Jn a arther embodiment, the unit dose form contains about 10 to about250 mg of the vmorelbine compound. In still a further embodunen1, the unit dose form con* about 15 to about I00 nlg of the vinorelbine compound In yet another embodiment, the unit dose form contains about 20 to about 75 mg of the vinorelbiie compound. In yet a further embodiment, the unit dose form contains about 25 to about 50 mg of the vinorelbime compound. In another 20 embodiment, the unit dose form contak about 31) to about 40 mg of the vinorelbine compound. In yet another embohment, the unit dose form contains about 240 to about 300 mg of the vmorelbine compound. In a further embodiment, the unit dose formcontains about at least about 120 mg. In still a further embodiment, the unit dose form contains at least abut 160 mg. In another embodiment, the unit dose form contains at Ieast about 240 mg. 25 In one embodiment, i.v. infusion dosages of the vinorelbine compound are from about 5 to about 25 mgL. The initial infusion dosage of the vinarelbine compound may be more or less, as determined by the treating physician. In one embodiment, the i.v. infusion dosage ofthe vinmelbm compound is about 10 to about 20 m&. In a further embodiment, the i.v. infusion dosage of the vinorelbine compound is about 20 to about 25 mgL. In yet another embodiment, 30 the 1.v. infusion dosage of the vinorelbine compound is at least about 10 mg/L. In another embodiment, the i.v infUsion dosage of the mnorelbine compound is at least about 15 mg/L. In yet another embodiment, the 1.v. rnfusion dosage of the vinorelbine compound is at least about 20 23 mgL. In yet another ernbodiment,the i.v infusion dosage of the vinorelbine compound is at least about 25 mg/L Precise dosages are determined by the administemg physician based on experlence wth theindividual subject to be treated Other dosage regimens and variations are foreseeable, and are deteimined through physician guidance. In one embodiment, the vinorelbine 5 compound is admuustered by 1.v. infusion or orally, preferably in the form of tablets or capsules. As described herein, subtherapeuticaUy effective amounts of the HKI-272 compound and v~norebll ne compound ma) be used to achieve atherapeutic effect when administered in cornbinahon In one embodiment, the HKI-272 compound is provided 4t dosages of 5 to 50% lower when provlded dong with the vinorelbine compound. In another embodiment, the HKI- 10 272 compound is provided at dosages of 10 to 25% lower when providedalong with the vinorelbine compound. In a further embodiment, the HKI-272 compound is provided at dosages of 15 to 20% lower when provided along with the vinorelbme compound. In one embodiment, a resulting HICI-272 compound dwage is about 8 to 40 mg. In another embodiment, a resulting HKI-272 compound dosage is about 8 to 30 mg In a further embodimenf a resulting HKI-272 15 compound dosage is about 8 to 25 mg. Subtherapeutically effective amounts of the HKI-272 compound and vmorelb~nec ompound are expected to redvce the side-effects of treatment. Alternatively, one or more ofthe active agents in the combination described herein is to be used in a suprathsrc+peutic amount, i.e., at a higher dosage in the combination than when used alone In th~se mbodiment, the other active agent(s) are used in a therapeutic or subtherapeutic 20 amount. Regimen Using the HECI-272 Compound and Vinorelbhe Compound As used herem, the components ofthe therapeutic "combined" regimen, is., the HKI-272 compound and the vinorelbine compound, can be administered simultaneously. Alternatively, 25 the two components can be administered in a staggered regimen, r.e., with theHKI-272 compound being given at a different bme during the course of chemotherapy than the vinorelbine compound This time differential may range from several minutes, hours, days, weeks, or longer between admirustratlon of the at least two agents. Therefore, the term combination (or combined) does not necessarily mean administered al the same bme or as a unitary dose or single 30 composition, but that each of the components are administered during a desired treatment period. The agents may also be administered by different routes. As used herein in one embodiment, 1 "cycle" includm 3 weeks 24 These regmens or cycles may be repeated, or alternated, as desired. Other dosage regimens and vanations are foreseeable, and we determined through physician guidance. The regimen mav Include ''non-treatment" steps/visits including screening periods aad post-treatment per~ods In one embodimen$ the regimen continues at least about 2 weeks, at least about 6 weeks, 5 at least about 12 weeks, at least about 24 weeks, at least about 33 weeks, at least about 40 weeks, and at least about 46 weeks. Additional screening weeks and final monitoring weeks may also be included. For example, the regmen may include 4 weeks of screening and 6 week for final visit. Smgle doses and multiple doses are contemplated. In one embodiment, the vinorelbi andlor HKI-272 compound is administered only once in the treatment. In another embodiment, 10 the heinorelbine andlor HKI-272 compound is administered at least once over a period of 21 days. In a further embodiment, the vinorelbine andfor HKI-272 compound is administered at least twice over a per~odo f 21 days. In still another embodiment, the vinorelbine a d o rH KI-272 compound is administered on days 1, 2, 3,4, 5,6,7, 8, 9, 10, 11, 12,13,14, 15,16, 17, 18, 19,20,Bndlor21 of the cycle In a further embodiment, the vinorelbine and/or HKI-272 compound is administered 15 on days 1 and 8 of the cycle. In still a M e r embodiment, the vinorelbine and/orHKI-272 compound is administered at least once daily In yet another embodiment, the vinom1bine andlor HW-272 compound HKI-272 compound is administered on day 1. Desirably, theHKI-272 compound is admimstered on day 1 if the neoplasm is non-metastatic. In afurther embodiment, the vinorelbine andlor HKI-272 compound is administered on day 2 of said regimen. Desirably, 20 the HW-272 compound is administered on day 2 if theneoplasm is metastatic. In still afurther embodiment, the HKI-272 compound is administered orally at least once a day. b mother embodrment, the M-272 compound is administered at least 1,2,3,4,5, or 6 times a day. In a further embodiment theHKI-272 compound is administered 1 to 4 times aday. In one embodiment, a smgle loading dose of the vinorelbine compound and/or HKI-272 25 compound 1s administered. The single loading dose of the vinoreIbine compound and/or the HW-272 compound may be the same dose as the subsequent doses or the single loading dose may be greater than the dose admmistered to the patient throughout the remaining treatment. In a further embodiment, the vinorelbiie compound /or the HKI-272 compound may be administered at a larger dose only once per cycle, t e., one day per cycle. 30 If certainsubjects do not tolerate one or more of the components of the composition, te., the HKI-272 compound or ~inorelbinec ompound or if the subject does not recover ftom treatment-related toxicity after more than 3 consecuime weeks, or if any grade 4 nonhematologic 25 toxtclty occurs that is treatment related, a dose reduction may be performed. In one embodiment, administration of one or both of the HKI-272 compound and the vinorelbine compound is &sconQnued if patent acquires one or more of a symptom including, without limitation, selected from the group consisting of neuropathy, neutropenia, thrombocytopenia, nausea, vomiting, 5 decreased platelet count, and increased bilirubin count. In another embodiment, administration of one or both of the HKI-272 compound and the vinorelblne compound is discontinued or intermpted if the patient's neutrophil count of is less than about 1000L. In a further embodiment, adminurattion of one or both of theHKI-272 compound and the vinorelbiie compound is discontinued or intermpted if the patient's platelet count is less than 75,000L. 10 Altemahsely, for those subjects do not tolerate one or more of the components of the composition, i e , the HKI-272 compound or vinorelbiie compound, dose reductions may be performed In one embodiment, 1 or 2 dose reductions are performed. More desirably, only 1 dose reduction is performed For subjects who not recover from vinorelbine or HKI-272-related toxicity after more than 15 3 consecuhve weeks, treatment with vinorelbme or HKI-272, respectively, may be discontinued However, administration of the other agent i.e., HKI-272 or vinorelbine, respectively, may be contmued The regimen is typically continued for at least about 2 weeks. In one embodiment, the regimen is continued for no more than 46 weeks. In another embodiment, the regiment is 20 continued for about 6 weeks. The length of parheipationis dependent on a subject's tolerance of the treatment and status of his or her disease. However, the treating physician may determine that shorter or longer treatment can be pursued For example, subjects may receive more than 12 cycles of treatment if it is well tolerated, if the neoplasm has not progressed, if the subject is cllnicdly stable, and if the subject has received an overall benefit. 25 In addition, the vlnorelbine compound lor the HKI-272 compound may also be administered after completion of chemotherapy as maintenance therapy. Pharmaceutical Packs and Kits Also included is a product or pharmaceutical pack contamng a come of an anti- 30 neoplastic treatment for one mdlvidual mammal comprising one or more container(s) having one, one to four, or more unit($ of the HKI-272 oompound in unit dosage form an4 optionally, one, one lo four, or more unit(s) of the HKI-272 and vinorelbine compouods, and optionally, another active agent. The combinations may be in the form of a kit of parts. In one embodiment a kit includes a first container with a suitable composition containing aHKI-272 compound and a second contamer with a suitable composition containing a 5 vtnorelbtne compound. Accordingly, there is promded a kit for use m the treatment or prophylaxis of cancer Th~kst t includes comprising, a) HKI-272 compound together with a phammceuhcally-acceptable exclpient or carrier, ina fmt unit dosage fonn; b) a vinorelbine compound together with a pharmacemcally-acceptable excipient or carrier, in a second unit dosage form, and c) a container for containing sad first and second dosage form. 10 In another embodiment, pharmaceutical packs contain a course of anti-neoplastic treatment for one individual mammal comprising a container having a uait of a HKI-272 compound in unit dosage form, a containiig having a unit of avinorelbine compound, and optionally, a contruner wlh another active agent In some embodiments, the compositions are in packs in aformready for administration. 15 In other embodiments, the compositions are in concentrated fotmin packs, oflonally with the dlluent required to make a fhal solution for administration. In still other embodiments, the product contams a compound described herein in solid formand, optionally, a separate container with a suitable solvent or camier. In shll other embodunents, the above packs/kits include other components, e.5, 20 ~nstructlonsf or dtluhon, m i n ga nd/or administrahon of the product, other containers, syringes, needles, elc. Other such packkit components are readily apparwt to one of skill in the art. Concurrent Treatments In addttion to the optional chemotherapeutic agents and optional compounds noted above, 25 the reglmens and methods described herein can be performed prior to, concurrently with, or subsequent to other non-medication procedures. In one embodiment, radiation may be performed pnor to, concurrently wi~o,r s ubsequent to treatment with the HKI-272 and vinorelbiie compounds 30 Preferred Embodiments In one embobmenf a regimen for treating a solid tumor associated with overexpr~ssiono r amplification of HER-;! in a subject is provided. One cycle of the regimen includes 21 days and 27 the regmen includes orally administering alleast one unit dose of HKI-272 starting on day 1 of the cycle and intravenously admirstenng at least one a unit dose of vinorelbine on days 1 and 8 of the cycle In mother embodiment, a regimen for treating a mematic cancer associated with 5 overexpression or ampl~ficationo f HER-2 in a subject is provided One cycle of the regmen icludes 21 days and the regimen includes orally administering at least one unit dose of HKI-272 starting on day 2 of the cycle and ~ntraver~ousalyd ministering at least one unit dose of vinorelbine on days 1 nnd 8 of the cycle. In a further embodiment, aproduct con- vino~elbiiea nd HIU-272 is provided. The 10 product is usem as a combmed preparation for simultaneous, separate or sequential use in treating a neoplasm in ammmal. In .Ml a further embodiment, a phmceuhcal pack for treating a neoplasm in one indtv~d ual mammal is provided. The pbmaceutical pack contains at least one unit of vinorelbine and at Leist one a t of HKI-272. 15 In another embod~menta, pharmaceuacal composition is provided and contains vinorelbine, HIU-272, and at least one pharmaceutically acceptable carrier. Desirably, the pharmaceu~cal composition is useful for treating aneoplasm in a ma& In still another embodiment, a method of treating aneoplasm associated with overexpression or amplification of HER-2 in a mammal in need thereof is provided The method 20 ~ncludesa dministering a umt dose of a vinorelbine compound and administe~ga unit dose of a HKI-272 compound. The followmg examples illustrate of the ususes of the combinations of the invention It will be readily understood that alterations or modifications, e.g., in the formulation of the 25 components, the routes of delivery, and the dosing, can be made for reasons known to those of skill m the art. EXAMPLE 1 COMBINATION REGIMEN OF HKI-272 AND VINORELBINEIN LUNG CANCER CELL PROLIFERATION ASSAYS 30 A standard cell proliferation assay was ut~l~zteod i ndependently analyze the response of lung cell hnes NCI-H1666, NCI-H1650, and NCI-HI975 to various dilutions of HKI-272 and vinorelbiie in combinat~on. Briefly, fetal bovine senun (FBS) RPMI-1640 (Media) was added 28 to each well of 96 well plates contai~xryo ne of the cell lines. Each column of wells contained a different dilution of HKI-272 and solutions of vinorelbine were added to each well at a variety of d~lui~owns11 1 respect to the HKI-272 dilutions (thehighest final concentration of HKI-272 was 1 pM for the HI650 andH1666 cell luies; the highest final concentration of HKI-272 was 9 phi 5 for the Hl975 cell line; and the highest final ooncentration of vinorelbine was 0.1 pM for dl of the cell lines) Following incubaon of the cell plates at 37 'C, 5% C02 for 72 hours, cell proltferation was assessed. Cell proliferabon was reduced after incubation with HKI-272 and vinorelbine. 10 =AMPLE 2. GOMBINATION REGIMEN OF HKI-272 AND VINORELBINE IN TREATMENT OF NON-METASTATIC BREAST CANCERS Patients having diagnosed non-metastatic breast cancers are mated using a regimen of HKI-272 and vinorelb~ne Pabents are administeredHK1-272 at either dose level 1 or 2. Dosing of HKI-272 begins at cycle 1, day 1 with daily oral administration of HKI-272 at the dosages in 5 Table 3 HKI-272 1s taken orally on the remaining days of the each cycle. On those days that HKI-272 and vinorelbine are admtnistered on the same day, i.e., days 1 and 8 of the cycle, HKI- 272 is ah~n~slerpendo r to the vmorelbme mfuslon. Table 3 Dose Hyl-272 Dose Vinorelbint Dose Level [ms) (mglm 1 1 160 2 240 25 V~norelbmeis administered on days 1 and 8 of each 21-day cycle, provided that the combination of HKI-272 and vinorelbine is well tolerated and there is no evidence of disease progression. Vinorelbrne 1s administered intravenously using preferentially a central venous route, through a free-flowing IV Sine over approximately 10 minutes, followed by 125 mZ, of 25 saline solubon Infused over approximately 30 minutes. If the patlent has any senous side-effwts during the treatment, dose adjustments of HKI- 272 andlor vinorelbine are permitted. See, Tables 4 and 5. Table 4 Dose Adjustment HKI-2 -1 6.0- I L I 240 The -1 dose level is used only if dose reduction 1s required. b The dose 1 level is to be used as first level of dose reduction in case the deiined max~mumioleratedd ose is 240 mg. Table 5 I 1 I a. The -1 dose level is to be used only if dose reduction is needed. It is predicted that a decrease in tumor @;row& will be observed. EXAMPLE 3' COMJ3INATION REGIMEN OF HKI-272 AND VONORELBINE IN TREATMENT OF NETASTATIC BREAST CANCERS 15 Paents having diagnosed metastatic breast cancers are treated using aregimen ofHKI- 272 and vinorelbine Vinorelbme is administered on day 1 and day 8 of the cycle using the dosages described in Example 2 Table 3 or 5. The vinorelbine is administered over a 30-minute period using an inline filter and an automatic dispensing pump Optionally, antihistamine (diphenhydramine, 25 to 20 50 mg IV or the equivalent) 1s ahn~steredab out 30 minutes prior to vinorelbine Man. Dosing of HKT-272 begins at cyde 1, day 2 with daily oral administration of HKI-272 at the dosages provlded m Example 2, Table 3 or 4. HKI-272 is taken orally on the remaining days of the each cycle. 04 those days that HKI-272 and vinorelbine are administered on the same day, i e., day 8 of the cl cle, HW-272 is administered prior to the vinorelbine infusion. If the 25 patient has any serious side-effects duringthe treatment, the dose adjustments of HKI-272 andlor ~rmorelbinea re pentted. 30 It is predicted that a decrease in tumor growth will be observed. All patents, patent publications, articles, and other documents teferenced herein are incorporated by reference It will be clear to one of skill in the art that modifications can be 5 made to the speclfic embedments descnbed herem without depatting from the scope of the invention.
We Claim: 1. A pharmaceutical pack, comprising: i) a unit dose of vinorelbine or a pharmaceutically acceptable salt ereo of; and ii) 50-300 mg of ~)-N-(4-[3-chloro-4-(2-pyridinylmethoxy)anilin0]-3-cymo-7-ethoxy-6-quinoliny1)-4-(dimethylamino)-2-butenamide ("HKI-272") or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical pack further comprises instructions for dilution, mixing and/or administration, syringes, or needles. 2. The pharmaceutical pack as claimed in claim 1, wherein said HKI-272 or a pharmaceutically acceptable salt thereof is at least about 120 mg, at least about 160 mg, or at least about 240 mg. 3. The pharmaceutical pack as claimed in any one of claims 1-2, wherein the unit dose amount of said vinorelbine or a pharmaceutically acceptable salt thereof is between 5-500 mg, 20-250 mg, or at least 240 mg. 4. The pharmaceutical pack as claimed in any one of claims 1-3, wherein the pharmaceutical composition is delivered intravenously. 5. The pharmaceutical pack as claimed in any one of claims 1-3, wherein one or both of said vinorelbine or a pharmaceutically acceptable salt thereof and said HKI-272 or a pharmaceutically acceptable sall thereof are delivered intravenously. 6. The pharmaceutical pack as claimed in any one of claims 1-4, wherein the unit dose amount of said vinorelbine or a pharmaceutically acceptable salt thereof is about 20 to about 25 mpn. 7. The pharmaceutical pack as claimed in any one of claim 1-3, wherein the pharmaceutical composition is delivered orally. 33 8. The pharmaceutical pack as claimed in any one of claims 1-3, wherein one or both of said vinorelbine or a pharmaceutically acceptable salt thereof and said HKI-272 or a pharmaceutically acceptable salt thereof are delivered orally. 9. The pharmaceutical pack as claimed in any one of claims 1-3 or 7-8, wherein the unit dose is a tablet. 10. The pharmaceutical pack as claimed in any one of claims 1-9, wherein said pharmaceutical composition is usehl in treating a neoplasm associated with overexpression or amplification of HER-2. 1 1. The pharmaceutical pack as claimed in claim 10, wherein the neoplasm is selected from the group consisting of a lung cancer, breast cancer, myeloma, prostate cancer, head and neck cancer, transitional cell carcinoma, small cell neuroendocrine carcinoma of the uterine cervix, and large cell neuroendocrine carcinoma of the uterine cervix. 12. The pharmaceutical pack as claimed in claim 11, wherein the neoplasm is a breast cancer. 13. The pharmaceutical pack as claimed in claim 12, wherein the neoplasm is metastatic. 14. The pharmaceutical pack as claimed rn claim 13, wherein the neoprasm is an advanced solid tumor. 15. The pharmaceutical pack as claimed in any one of claims 1-9, wherein said pharmaceutical composition is useful in treating a metastatic, HER-2-positive breast cancer.